Cargando…
Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071342/ https://www.ncbi.nlm.nih.gov/pubmed/30122853 http://dx.doi.org/10.4103/meajo.MEAJO_6_18 |
_version_ | 1783343854716452864 |
---|---|
author | Shields, Carol L. Welch, R. Joel Malik, Kunal Acaba-Berrocal, Luis A. Selzer, Evan B. Newman, Jennifer H. Mayro, Eileen L. Constantinescu, Alexandru B. Spencer, Meredith A. McGarrey, Mark P. Knapp, Austen N. Graf, Alexander E. Altman, Alex J. Considine, Sean P. Shields, Jerry A. |
author_facet | Shields, Carol L. Welch, R. Joel Malik, Kunal Acaba-Berrocal, Luis A. Selzer, Evan B. Newman, Jennifer H. Mayro, Eileen L. Constantinescu, Alexandru B. Spencer, Meredith A. McGarrey, Mark P. Knapp, Austen N. Graf, Alexander E. Altman, Alex J. Considine, Sean P. Shields, Jerry A. |
author_sort | Shields, Carol L. |
collection | PubMed |
description | PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan–Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. |
format | Online Article Text |
id | pubmed-6071342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60713422018-08-17 Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin Shields, Carol L. Welch, R. Joel Malik, Kunal Acaba-Berrocal, Luis A. Selzer, Evan B. Newman, Jennifer H. Mayro, Eileen L. Constantinescu, Alexandru B. Spencer, Meredith A. McGarrey, Mark P. Knapp, Austen N. Graf, Alexander E. Altman, Alex J. Considine, Sean P. Shields, Jerry A. Middle East Afr J Ophthalmol Original Article PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan–Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6071342/ /pubmed/30122853 http://dx.doi.org/10.4103/meajo.MEAJO_6_18 Text en Copyright: © 2018 Middle East African Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Shields, Carol L. Welch, R. Joel Malik, Kunal Acaba-Berrocal, Luis A. Selzer, Evan B. Newman, Jennifer H. Mayro, Eileen L. Constantinescu, Alexandru B. Spencer, Meredith A. McGarrey, Mark P. Knapp, Austen N. Graf, Alexander E. Altman, Alex J. Considine, Sean P. Shields, Jerry A. Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin |
title | Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin |
title_full | Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin |
title_fullStr | Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin |
title_full_unstemmed | Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin |
title_short | Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin |
title_sort | uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071342/ https://www.ncbi.nlm.nih.gov/pubmed/30122853 http://dx.doi.org/10.4103/meajo.MEAJO_6_18 |
work_keys_str_mv | AT shieldscaroll uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT welchrjoel uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT malikkunal uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT acababerrocalluisa uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT selzerevanb uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT newmanjenniferh uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT mayroeileenl uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT constantinescualexandrub uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT spencermereditha uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT mcgarreymarkp uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT knappaustenn uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT grafalexandere uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT altmanalexj uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT considineseanp uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin AT shieldsjerrya uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin |